TABLE 1.
Frizzled receptors and associated miRNA in cancer.
| Frizzled | Cancer | miRNA | Activity |
|---|---|---|---|
| Fzd1 | Gastric | miR135a | Decreased angiogenesis (Cheng et al., 2017a) |
| miR-8052 | Decreased EMT, proliferation, and metastasis (Sun et al., 2020) | ||
| NSCLC | miR-135b | Reversed chemoresistance (Su et al., 2016) | |
| Fzd2 | ESCC | miR30a-3p | Decreased Wnt/β-catenin pathway Potential biomarker (Qi et al., 2017) |
| miR-30a-5p | |||
| Cervical | miR-17-5p | Increased drug sensitivity (Xu et al., 2019a) | |
| Breast | miR-34a | Decreased Wnt/β-catenin signaling (Bonetti et al., 2020) | |
| Lung | miR-203 | Cell migration, metastasis, Wnt/β-catenin pathway (Mine et al., 2015) | |
| Fzd3 | CLL | miR-607 | Induced apoptosis, decreased Wnt/β-catenin signaling (Xia et al., 2018) |
| AML | miR-155 | Inhibited AML progenitor cell transformation, proliferation, and differentiation (Zhang et al., 2017) | |
| miR-192 | |||
| Fzd4 | NSCLC | miR-3127-5p | Decreased EMT via Wnt/β-catenin inhibition (Yang et al., 2018) |
| miR-204 | Targeted a Fzd4/miR/SNP loci to downregulate Fzd4 expression. Associated with increased survival in early stages (Lin et al., 2017) | ||
| miR-515-5p | Decreased migration and invasion (Pardo et al., 2016) | ||
| Cervical | miR-505 | Decreased cell proliferation and invasion (Ma C et al., 2017) | |
| Pancreatic | miR-29c | Suppressed Fzd4 and LRP6 expression to inhibit Wnt/β-catenin signaling (Jiang et al., 2015) | |
| Bladder | miR-101 | Decreased cell migration and metastasis (Chen et al., 2019) | |
| miR-493 | |||
| Liver | miR-Let7 | Decreased stemness of liver cancer cells (Cai et al., 2017) | |
| Prostate | miR-377 | Decreased EMT via Wnt/β-catenin inhibition (Formosa et al., 2014) | |
| Fzd5 | OSCC | miR-224-5p | Inhibited cell proliferation and colony formation (Zhang, 2017) |
| HCC | miR-29c | Suppressed Fzd4 and LRP6 expression to inhibit Wnt/β-catenin signaling (Jiang et al., 2015) | |
| Pancreatic | miR-1324 | Decreased proliferation, migration, and invasion via Wnt/β-catenin signaling inhibition (Zhu et al., 2018) | |
| Fzd6 | Colorectal | miR-199a-5p | Decreased invasiveness via non-canonical WNT signaling (Kim et al., 2015) |
| Glioblastoma | miR-20b | Altered regulation of mesenchymal phenotype through STAT3 and NF-kB (Huang et al., 2016) | |
| miR-125b | |||
| OSCC | miR-302b | Decreased metastasis (Sun et al., 2021) | |
| Fzd7 | HCC | miR-199a | Decreased cell proliferation and survival (Song et al., 2014) |
| miR-542-3p | Decreased cell growth (Wu et al., 2017a) | ||
| miR-504 | Supported tumor-suppressive phenotype (Quan et al., 2018) | ||
| miR-485-5p | Decreased tumor progression (Wang et al., 2018a) | ||
| Melanoma | miR-485-5p | Decreased cell invasion and proliferation (Wu et al., 2017b) | |
| CRC | miR-944 | Decreased doxorubicin resistance and tumor progression (Xi et al., 2021) | |
| Colon | miR-23b | Screened as potential inhibitor of metastasis (Zhang et al., 2011) | |
| Glioblastoma | miR-144-3p | Tumor suppressor and predictive marker for prognosis (Cheng et al., 2017b) | |
| miR-504 | Suppressed EMT signaling (Liu et al., 2019a) | ||
| Glioma | miR-206 | Decreased cell proliferation, migration, and invasion (Zhou et al., 2019) | |
| Cervical | miR-142-3p | Decreased cell proliferation and invasion (Deng et al., 2015) | |
| RCC | miR-613 | Decreased cell proliferation and invasion (Song et al., 2017) | |
| Prostate | miR-613 | Decreased cell proliferation and invasion (Ren et al., 2016) | |
| Breast | miR-1 | Inhibited cell proliferation and migration of breast stem cells (Liu et al., 2015) | |
| Gastric | miR-27b | Reduced MDR1/P-glycoprotein and β-catenin expression, reduced chemoresistance (Geng et al., 2016) | |
| Fzd8 | Colorectal | miR-375 | Suppressed metastasis (Xu et al., 2016) |
| Spinal osteosarcoma | miR-520b | Decreased cell proliferation, migration, and invasion (Wang et al., 2017) | |
| Thyroid | miR-370-3p | Decreased cell proliferation and invasion (Chen et al., 2018) | |
| Fzd9 | NSCLC | miR-31 | Decreased EMT signaling (Tennis et al., 2016) |
Fzd10 was not included in the table as no miRNAs have been identified. NSCLC, non–small-cell lung cancer; ESCC, esophageal cancer; CLL, chronic lymphocytic leukemia; AML, acute myeloid leukemia; OSCC, oral squamous cell carcinoma; HCC, hepatocellular carcinoma; CRC, colorectal cancer; RCC, renal cell carcinoma.